← Companies|Abdi Ibrahim
Ab

Abdi Ibrahim

Istanbul TRFounded 19125,000 employees
Private CappharmaPrivateOncologyCardiology
Platform: Turkish Pharma
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
ABD-5382ABD-5382Preclinical1Cell TherapyCD38Anti-AβProstate CaACC
LisotapinarofABD-646NDA/BLA2siRNACD38VEGFiCFNMOSD
ABD-3507ABD-3507Preclinical2Cell TherapyVEGFCDK2iDravetMigraine
AdagranesiranABD-9046Phase 21Small MoleculeUSP1TROP-2 ADCLGS
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (4)
2026-08-17
ABD-3507 Interim
Dravet
Interim
2027-06-23
ABD-5382 Interim
ACC
Interim
2028-08-21
Lisotapinarof Ph3 Readout
NMOSD
Ph3 Readout
2030-10-26
Adagranesiran Ph2 Data
LGS
Ph2 Data